Table 6.

Secondary outcome – Adverse Events - Pain

Comparison*	Number of sites (primary studies)	Measure of effect	Effect model	Direction of effect	Follow up	Heterogeneity
Envelope vs triangular flap	100 vs 100 (3)	MD= 0.25; 95% CI (–0.82, 1.33)	Random	No difference	1 day	I2=86%
Envelope vs triangular flap	139 vs 139 (5)	MD= –0.01; 95% CI (–0.81, 0.79)	Random	No difference	2 days	I2=80%
Envelope vs triangular flap	140 vs 140 (5)	MD= 0.06; 95% CI (–0.08, 0.21)	Random	No difference	3 days	I2=82%
Envelope vs triangular flap	100 vs 100 (3)	MD= –0.40; 95% CI (–1.20, 0.39)	Random	No difference	4 days	I2=85%
Envelope vs triangular flap	68 vs 68 (2)	MD= –0.28; 95% CI (–0.93, 0.36)	Random	No difference	5 days	I2=52%
Envelope vs triangular flap	68 vs 68 (2)	MD= –0.41; 95% CI (–0.75, –0.07)	Random	Favors envelope flap	6 days	I2=0
Envelope vs triangular flap	181 vs 175 (6)	MD= –0.02; 95% CI (–0.23, 0.19)	Random	No difference	7 days	I2=57%
PRF vs Spontaneous healing	499 vs 499 (15)	SMD= –0.60; 95% CI (–1.00, –0.20)	Random	Favors PRF	1 day	I2=89.1%
PRF vs Spontaneous healing	504 vs 504 (17)	SMD= –0.86; 95% CI (–1.26, –0.46)	Random	Favors PRF	3 days	I2=88.7%
PRF vs Spontaneous healing	473 vs 473 (15)	SMD= –0.76; 95% CI (–1.14, –0.38)	Random	Favors PRF	7 days	I2=86.7%
L-PRF vs Spontaneous healing	67 vs 67 (3)	MD= –0.98; 95% CI (–1.65, –0.32)	Random	Favors L-PRF	1 day	I2=28%
L-PRF vs Spontaneous healing	67 vs 67 (3)	MD= –1.07; 95% CI (–1.53,–0.60)	Fixed	Favors L-PRF	3 days	I2=68%
HyA application vs Control	120 vs 114 (4)	MD= 0.52; 95% CI (–0.34, 1.38)	Random	No difference	2–3 days	I2=0
HyA application vs Control	140 vs 134 (5)	MD= 0.32; 95% CI (0.12, 0.51)	Random	Favors HyA	7 days	I2=0

VAS visual analogue scale, PRF platelet rich fibrin, L-PRF leukocyte - platelet rich fibrin, MD mean difference, SMD standardized mean difference, CI confidence interval, HyA hyaluronic acid

*Outcome measure: VAS pain score